Latest Pharmaceutical Patents News

Race Oncology has uncovered that its anticancer drug bisantrene exists as three light-sensitive isomers, with only one showing potent activity. The company has filed patents to protect this active form, potentially extending its intellectual property rights until 2045.

Argenica Therapeutics has dosed the final patient in its Phase 2 trial for ARG-007 in acute ischaemic stroke, with topline results expected in Q3 2025. Meanwhile, the FDA has placed a clinical hold on its US trial application, introducing uncertainty for US development.

Anatara Lifesciences has strengthened its intellectual property portfolio with a Japanese patent for its GaRP gastrointestinal health product, while progressing pre-clinical studies in its Anti-Obesity Project. The company also confirmed registration of its R&D Tax Incentive application for 2024-2025.

Recce Pharmaceuticals has secured a significant patent acceptance in China for its RECCE® anti-infectives, broadening its intellectual property footprint in the world’s second-largest pharmaceutical market.

Argenica Therapeutics has expanded its intellectual property with a new US patent targeting surgically induced strokes, enhancing the commercial potential of its lead drug candidate ARG-007.

Anatara Lifesciences has expanded its intellectual property footprint with a 20-year patent granted in Hong Kong for its GaRP gastrointestinal health product, following similar approvals in Europe and Australia. This milestone strengthens its commercial position in the lucrative global market for digestive health solutions.

Immutep Limited has dosed the first patient in its pivotal Phase III lung cancer trial and completed enrolments in multiple studies, supported by a robust cash position expected to fund operations through 2026.